A Phase II Study of Entinostat plus Pembrolizumab Immunotherapy for Recurrent or Persistent Lymphoma

Full Title

A Phase II Study of Pembrolizumab and Entinostat in Patients with Relapsed and Refractory Lymphomas

Purpose

The purpose of this study is to assess the safety and effectiveness of combining the investigational immunotherapy drug entinostat with the immunotherapy drug pembrolizumab in patients with Hodgkin lymphoma or follicular lymphoma that has come back or continued to grow despite other treatments. Entinostat is thought to reduce the number of certain cells that prevent the immune system from functioning well. Pembrolizumab boosts the power of the immune system to recognize and kill cancer cells by blocking a protein called PD-1.

Entinostat is taken orally (by mouth), and pembrolizumab is given intravenously (by vein). Pembrolizumab is approved to treat several types of cancer, including Hodgkin lymphoma; its use in this study is considered investigational.

Eligibility

To be eligible for this study, patients must meet several criteria, including but not limited to the following:

  • Patients must have Hodgkin lymphoma or follicular lymphoma that has come back or continued to grow despite at least two prior regimens of therapy.
  • At least 2 weeks must pass between the completion of prior therapy and entry into the study.
  • Patients must be physically well enough that they are fully ambulatory, capable of all self care, and are capable of all but physically strenuous activities. As an example, patients must be well enough that they would be able to carry out office work or light housework.
  • This study is for patients age 18 and older.

For more information about this study and to inquire about eligibility, please contact Dr. Anas Younes at 212-639-7715.

Protocol

17-073

Phase

II

Disease Status

Relapsed or Refractory

Investigator

Co-Investigators